|Videos|July 20, 2016

Cognitive Decline Reversal in Alzheimer Disease

Dr. Bobby Lazzara discusses the first description of reversal of cognitive decline in early Alzheimer disease or its precursors.

Can cognitive decline in early Alzheimer disease or its precursors be reversed? In this Medical News Minute, developed exclusively for Neurology Times, Dr. Bobby Lazzara reviews a small study of ten patients treated with a programmatic and personalized therapeutic approach – metabolic enhancement for neurodegeneration (MEND).

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!

Cognitive Decline Reversal in Alzheimer Disease

Newsletter

Related Content

Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results

Analyzing Subgroup Data From the TRAILBLAZER-ALZ 2 Study of Donanemab: Brandy Matthews, MD

Newly Launched Phase POLARIS-AD Trial Tests Oral Therapy AR1001 for Early Alzheimer Disease

Brainstorming Ways of Improving Representation Across Alzheimer Disease Clinical Research: Sid O’Bryant, PhD

Autologous Stem Cell Approach Shows Promising Early Phase 1 Data in Alzheimer Disease

Latest CME

Identifying and Treating CIDP in the Modern Era

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

CTAD Presentation Lays Insights Into Disappointing Phase 3 EVOKE Trial of GLP-1 Semaglutide in Alzheimer Disease

Newly Launched Phase POLARIS-AD Trial Tests Oral Therapy AR1001 for Early Alzheimer Disease

New Clarity AD Analysis Reveal How Lecanemab Engages and Clears Neurotoxic Protofibrils in Alzheimer Disease

Autologous Stem Cell Approach Shows Promising Early Phase 1 Data in Alzheimer Disease

Analyzing Subgroup Data From the TRAILBLAZER-ALZ 2 Study of Donanemab: Brandy Matthews, MD